DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT

Rob Jones; Bart Sheehan; Patrick Phillips; Ed Juszczak; Jessica Adams; Ashley Baldwin; Clive Ballard; Sube Banerjee; Bob Barber; Peter Bentham; Richard Brown; Alistair Burns; Tom Dening; David Findlay; Richard Gray; Mary Griffin; Clive Holmes; Alan Hughes; Robin Jacoby; Tony Johnson; Roy Jones; Martin Knapp; James Lindesay; Ian McKeith; Rupert McShane; Ajay Macharouthu; John O'Brien; Caroline Onions; Peter Passmore; James Raftery; Craig Ritchie; Rob Howard; DOMINO-AD team

doi:10.1186/1745-6215-10-57

DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT

Rob Jones, Bart Sheehan, Patrick Phillips, Ed Juszczak, Jessica Adams, Ashley Baldwin, Clive Ballard, Sube Banerjee, Bob Barber, Peter Bentham, Richard Brown, Alistair Burns, Tom Dening, David Findlay, Richard Gray, Mary Griffin, Clive Holmes, Alan Hughes, Robin Jacoby, Tony JohnsonRoy Jones, Martin Knapp, James Lindesay, Ian McKeith, Rupert McShane, Ajay Macharouthu, John O'Brien, Caroline Onions, Peter Passmore, James Raftery, Craig Ritchie, Rob Howard, DOMINO-AD team

Research output: Contribution to journal › Article › peer-review

41 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is the commonest cause of dementia. Cholinesterase inhibitors, such as donepezil, are the drug class with the best evidence of efficacy, licensed for mild to moderate AD, while the glutamate antagonist memantine has been widely prescribed, often in the later stages of AD. Memantine is licensed for moderate to severe dementia in AD but is not recommended by the England and Wales National Institute for Health and Clinical Excellence. However, there is little evidence to guide clinicians as to what to prescribe as AD advances; in particular, what to do as the condition progresses from moderate to severe. Options include continuing cholinesterase inhibitors irrespective of decline, adding memantine to cholinesterase inhibitors, or prescribing memantine instead of cholinesterase inhibitors. The aim of this trial is to establish the most effective drug option for people with AD who are progressing from moderate to severe dementia despite treatment with donepezil.

Original language	English
Article number	57
Pages (from-to)	57
Journal	Trials
Volume	10
DOIs	https://doi.org/10.1186/1745-6215-10-57
Publication status	Published - 24 Jul 2009

ASJC Scopus subject areas

Medicine (miscellaneous)
Pharmacology (medical)

Access to Document

10.1186/1745-6215-10-57

Cite this

Jones, R., Sheehan, B., Phillips, P., Juszczak, E., Adams, J., Baldwin, A., Ballard, C., Banerjee, S., Barber, B., Bentham, P., Brown, R., Burns, A., Dening, T., Findlay, D., Gray, R., Griffin, M., Holmes, C., Hughes, A., Jacoby, R., ... DOMINO-AD team (2009). DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT. Trials, 10, 57. Article 57. https://doi.org/10.1186/1745-6215-10-57

@article{c5ef4966bfba4407a7afb2cdf65fe78e,

title = "DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT",

abstract = "Alzheimer's disease (AD) is the commonest cause of dementia. Cholinesterase inhibitors, such as donepezil, are the drug class with the best evidence of efficacy, licensed for mild to moderate AD, while the glutamate antagonist memantine has been widely prescribed, often in the later stages of AD. Memantine is licensed for moderate to severe dementia in AD but is not recommended by the England and Wales National Institute for Health and Clinical Excellence. However, there is little evidence to guide clinicians as to what to prescribe as AD advances; in particular, what to do as the condition progresses from moderate to severe. Options include continuing cholinesterase inhibitors irrespective of decline, adding memantine to cholinesterase inhibitors, or prescribing memantine instead of cholinesterase inhibitors. The aim of this trial is to establish the most effective drug option for people with AD who are progressing from moderate to severe dementia despite treatment with donepezil.",

author = "Rob Jones and Bart Sheehan and Patrick Phillips and Ed Juszczak and Jessica Adams and Ashley Baldwin and Clive Ballard and Sube Banerjee and Bob Barber and Peter Bentham and Richard Brown and Alistair Burns and Tom Dening and David Findlay and Richard Gray and Mary Griffin and Clive Holmes and Alan Hughes and Robin Jacoby and Tony Johnson and Roy Jones and Martin Knapp and James Lindesay and Ian McKeith and Rupert McShane and Ajay Macharouthu and John O'Brien and Caroline Onions and Peter Passmore and James Raftery and Craig Ritchie and Rob Howard and {DOMINO-AD team}",

year = "2009",

month = jul,

day = "24",

doi = "10.1186/1745-6215-10-57",

language = "English",

volume = "10",

pages = "57",

journal = "Trials",

publisher = "BioMed Central",

}

Jones, R, Sheehan, B, Phillips, P, Juszczak, E, Adams, J, Baldwin, A, Ballard, C, Banerjee, S, Barber, B, Bentham, P, Brown, R, Burns, A, Dening, T, Findlay, D, Gray, R, Griffin, M, Holmes, C, Hughes, A, Jacoby, R, Johnson, T, Jones, R, Knapp, M, Lindesay, J, McKeith, I, McShane, R, Macharouthu, A, O'Brien, J, Onions, C, Passmore, P, Raftery, J, Ritchie, C, Howard, R & DOMINO-AD team 2009, 'DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT', Trials, vol. 10, 57, pp. 57. https://doi.org/10.1186/1745-6215-10-57

TY - JOUR

T1 - DOMINO-AD protocol

T2 - donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT

AU - Jones, Rob

AU - Sheehan, Bart

AU - Phillips, Patrick

AU - Juszczak, Ed

AU - Adams, Jessica

AU - Baldwin, Ashley

AU - Ballard, Clive

AU - Banerjee, Sube

AU - Barber, Bob

AU - Bentham, Peter

AU - Brown, Richard

AU - Burns, Alistair

AU - Dening, Tom

AU - Findlay, David

AU - Gray, Richard

AU - Griffin, Mary

AU - Holmes, Clive

AU - Hughes, Alan

AU - Jacoby, Robin

AU - Johnson, Tony

AU - Jones, Roy

AU - Knapp, Martin

AU - Lindesay, James

AU - McKeith, Ian

AU - McShane, Rupert

AU - Macharouthu, Ajay

AU - O'Brien, John

AU - Onions, Caroline

AU - Passmore, Peter

AU - Raftery, James

AU - Ritchie, Craig

AU - Howard, Rob

AU - DOMINO-AD team

PY - 2009/7/24

Y1 - 2009/7/24

N2 - Alzheimer's disease (AD) is the commonest cause of dementia. Cholinesterase inhibitors, such as donepezil, are the drug class with the best evidence of efficacy, licensed for mild to moderate AD, while the glutamate antagonist memantine has been widely prescribed, often in the later stages of AD. Memantine is licensed for moderate to severe dementia in AD but is not recommended by the England and Wales National Institute for Health and Clinical Excellence. However, there is little evidence to guide clinicians as to what to prescribe as AD advances; in particular, what to do as the condition progresses from moderate to severe. Options include continuing cholinesterase inhibitors irrespective of decline, adding memantine to cholinesterase inhibitors, or prescribing memantine instead of cholinesterase inhibitors. The aim of this trial is to establish the most effective drug option for people with AD who are progressing from moderate to severe dementia despite treatment with donepezil.

AB - Alzheimer's disease (AD) is the commonest cause of dementia. Cholinesterase inhibitors, such as donepezil, are the drug class with the best evidence of efficacy, licensed for mild to moderate AD, while the glutamate antagonist memantine has been widely prescribed, often in the later stages of AD. Memantine is licensed for moderate to severe dementia in AD but is not recommended by the England and Wales National Institute for Health and Clinical Excellence. However, there is little evidence to guide clinicians as to what to prescribe as AD advances; in particular, what to do as the condition progresses from moderate to severe. Options include continuing cholinesterase inhibitors irrespective of decline, adding memantine to cholinesterase inhibitors, or prescribing memantine instead of cholinesterase inhibitors. The aim of this trial is to establish the most effective drug option for people with AD who are progressing from moderate to severe dementia despite treatment with donepezil.

U2 - 10.1186/1745-6215-10-57

DO - 10.1186/1745-6215-10-57

M3 - Article

C2 - 19630974

VL - 10

SP - 57

JO - Trials

JF - Trials

M1 - 57

ER -

DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT

Abstract

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this